Abstract | BACKGROUND: It has already been shown that the production of fucosylceramide, an aberrant glycolipid, is associated with neoplastic changes in human tissues. The authors of this study designed a sandwich radioimmunoassay (RIA) using a mouse monoclonal anti- fucosylceramide antibody, PC47H, designated as PC/PC RIA, and measured the level of u-FCC, an antigen of PC47H, in the urine of cancer patients. METHODS: RESULTS: The rates of u-FCC positivity were 63% for patients with gastric carcinoma and 69% for colorectal carcinoma patients. The rate was only 1% (1/110) for the healthy individuals. The u-FCC value did not correlate with the values of either CA 19-9 or carcinoembryonic antigen (CEA). In a combination assay of u-FCC with CA 19-9 and CEA, the positivity rates were 84% for gastric carcinoma patients and 85% for colorectal carcinoma patients. CONCLUSIONS: Gastric and colorectal carcinoma patients have significantly high levels of u-FCC in their urine compared with normal individuals.
|
Authors | T Tanimizu, H Ishihara, H Hattori, S Hamada, R Hirayama |
Journal | Cancer
(Cancer)
Vol. 83
Issue 4
Pg. 660-5
(Aug 15 1998)
ISSN: 0008-543X [Print] United States |
PMID | 9708928
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antigens, Neoplasm
- Cerebrosides
- fucosylceramide
|
Topics |
- Animals
- Antibodies, Monoclonal
- Antigens, Neoplasm
(urine)
- Cerebrosides
(immunology)
- Cholelithiasis
(urine)
- Colorectal Neoplasms
(pathology, urine)
- Humans
- Mice
- Neoplasm Staging
- Radioimmunoassay
- Stomach Neoplasms
(pathology, urine)
- Stomach Ulcer
(urine)
|